12:00 AM
 | 
Jan 10, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ipratropium bromide: Began Phase I/II study

Sheffield Pharmaceuticals Inc. (SHM), St. Louis, Mo.
Product: Ipratropium bromide
Business: Drug delivery, Pulmonary
Therapeutic category: Receptor antagonist
Target:...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >